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Highlights 
● Microdeletions and intragenic variants in KMT2B are associated with early onset 
progressive dystonia, with predominant cervical and oromandibular involvement. 
● GPI-DBS should be considered early in the disease course, as medical therapy is of 
limited benefit. 
● Microarray should be included in first tier genetic testing in children and adults with 
dystonia.  
Abstract 
 
In 2016, two research groups independently identified microdeletions and pathogenic variants 
in the lysine-specific histone methyltransferase 2B gene, KMT2B in patients with early-onset 
progressive dystonia. KMT2B-dystonia (DYT28) is emerging as an important and frequent 
cause of childhood-onset progressive generalised dystonia and is estimated to potentially 
account for up to 10% of early-onset generalised dystonia. Herein, we review variants in 
KMT2B associated with dystonia, as well as the clinical phenotype, treatment and underlying 
disease mechanisms. Furthermore, in context of this newly identified condition, we 
summarise our approach to the genetic investigation of paediatric dystonia.   
Introduction  
 
Dystonia is a hyperkinetic movement disorder characterised by sustained or intermittent 
muscle contractions causing abnormal, often repetitive movements and postures affecting the 
limbs, trunk, neck and face. Dystonic movements are typically patterned, twisting, and may 
be tremulous, and they are often initiated or worsened by voluntary action and associated with 
overflow muscle activation.1 Childhood-onset dystonia may be acquired or genetic in origin, 
and can occur in isolation or in association with other movement disorders, neurological or 
systemic manifestations.1 
 
With the advent of next generation sequencing (NGS), new genetic causes of childhood-onset 
movement disorders have been identified, as well as phenotypic expansion of known dystonia 
genes.2-4 Despite these advances, a significant number of children and adults remain without a 
genetic diagnosis. It is likely that gene discovery in dystonia is complicated by reduced 
penetrance and intrafamilial variability, which make the interpretation of new variants more 
challenging. The identification of a genetic diagnosis is key to optimising clinical care, as it 
enables informed genetic counselling, disease prognostication and targeted disease-specific 
treatments.  
  
In 2016, two groups independently identified microdeletions and pathogenic variants in the 
lysine-specific histone methyltransferase 2B gene, KMT2B in patients with early onset 
progressive dystonia.5,6 KMT2B (Chr. 19:35,717,817-35,738,879 , hg38, OMIM 606834) has 
a key role in gene expression and transcription activation. Though only recently reported, 
KMT2B-dystonia (DYT28) is emerging as an important and frequent cause of childhood-
onset progressive generalised dystonia and may account for up to 10% of early-onset 
generalised dystonia.2 Herein, we review variants in KMT2B associated with dystonia, as well 
as the clinical phenotype, treatment and underlying disease mechanisms. Furthermore, in 
context of this newly identified condition, we summarise our approach to the genetic 
investigation of paediatric dystonia.  
 
Clinical characteristics 
 
To date, 43 patients with KMT2B variants are published including cases with microdeletions 
encompassing the gene (n=14), as well as intragenic predicted protein-truncating variants 
(PPTV) (n=17) and nonsynonymous missense variants (n= 12).5-9 The clinical phenotype is of 
an early onset progressive dystonia, which typically begins in the lower limbs. The dystonia 
becomes generalised over time (range 1-9 years, mean 4.4 years) with cervical (retrocollis 
and torticollis), oromandibular (facial dystonia, and bulbar-oromandibular) and laryngeal 
(dysphonia and spasmodic laryngeal spasm) involvement. Bulbar features are often 
predominant and present in the majority; some patients develop disabling dysarthria 
progressing to anarthria as well as swallowing difficulties necessitating percutaneous 
endoscopic gastrostomy (PEG) tube for nutrition.  Bulbar symptoms may be present at the 
onset of dystonia or develop over time.  The clinical phenotype of previously described cases 
is summarised in Table 1.  
 
Early phenotype-genotype correlation studies indicate that, chromosomal microdeletions and 
PPTV present at a statistically significant younger age, when compared to intragenic missense 
variants (mean age of 4.82 years compared to 11.75 years). In addition, patients with 
nonsynonymous variants have fewer co-existing systemic and neurological findings or pre-
existing development delay (Table 1) when compared to those with microdeletions or 
PPTVs. Dysmorphic features of an elongated face, broad nasal base, bulbous nasal tip, fifth-
finger clinodactyly or second and third syndactyly has been identified in some patients, and 
more frequently in those with microdeletions and PPTV. Other reported systemic features 
include preceding developmental delay (38%), intellectual disability (ID) (57%, mild to 
severe), microcephaly (21% of cohort, only reported in PPTV and microdeletions) and short 
stature (21%). Dermatological (cutis aplasia, abnormal scarring) systemic (renal and 
respiratory), ophthalmological (oculomotor apraxia, strabismus) and psychiatric symptoms 
are also reported in some individuals (Table 1). As with other dystonia genes, atypical 
phenotypes are reported including, dystonia presenting later in adulthood (Patient 26b5, 
Patient 37), paroxysmal cervical dystonia only (Patient 26a5), oromandibular dystonia with no 
lower limb dystonia (Patient 185), or only dystonia of lower limbs (Patient 105). 
 
Neuroimaging features 
Meyer and colleagues noted subtle, symmetrical hypointensity of the globus pallidi 
(especially the lateral aspect of the globus pallidus externa) on T2, diffusion and susceptibility 
weighted magnetic resonance imaging (MRI) images in 17 of 22 reviewed scans (Figure 1).5 
The significance of this hypointensity is unclear and may be an age-dependent finding. 
Patient age at the time of scan appears to influence MRI findings, as globus pallidus externa 
hypointensity was more prevalent in individuals who had neuroimaging performed at a 
younger age (average age of patients with abnormal imaging, 11.7 years; average age of 
patients with normal imaging 19 years) and in one patient was seen to diminish with 
increasing age.5  
 Treatment 
Dystonia-specific medications and levodopa trials have had minimal or no clinical benefit in 
patients with KMT2B-dystonia.  To date, 13 patients have had globus pallidus interna-deep 
brain stimulation (GPI-DBS, mean age of insertion 21.7 years, range 6-53 years) with a 
clinical response evident in all patients. In some patients after GPI-DBS, there was a 
remarkable improvement in motor function and return of independent ambulation.5-7 
Published data therefore suggests that GPI-DBS should be considered early in the disease 
course of KMT2B-dystonia. 
 
KMT2B Variants reported to date 
To date, 40 different variants are reported including heterozygous interstitial microdeletions 
(n=14), PPTV (frameshift, splice-site and stop-gain variants) (n= 15) and nonsynonymous 
variants of KMT2B (n=11) (Table 1).5-9 There are no recurring variants or mutation hotspots, 
though described variants are frequently located in key protein domains, including the 
catalytic SET domain.  The majority of the variants in KMT2B occurred de novo, but rarely 
autosomal dominant inheritance with reduced penetrance is reported. Symptomatic relatives 
(patient 26b5, F4-II-4 and F4-I-36) and asymptomatic carriers [mothers of patient 22 and 275, 
adult daughters (aged 32 and 34 years) of patient 37] are described. Symptomatic parents 
appear to have a milder phenotype than their children, often with later onset dystonia and 
fewer systemic features. Incomplete penetrance is not unique to KMT2B-dystonia and 
reported in many other genetic dystonia (DYT1, DYT25).2-4  
 
Disease Mechanisms in KMT2B dystonia 
KMT2B encodes lysine methyltransferase 2B, specifically involved in the methylation of 
histone H3 at lysine 4 (H3K4). This is an important epigenetic regulator involved in gene 
expression and transcription activation, considered essential for normal development and to 
maintain proper neural function. The underlying mechanism of how KMT2B causes dystonia 
is not fully elucidated. KMT2B is ubiquitously expressed during brain development and in the 
adult brain, with the highest expression in areas of motor control and cerebellum.5,13 KMT2B 
gene expression on qRT-PCR analysis was significantly reduced for microdeletion and PPTV 
variants compared to control fibroblasts.5,6 Preliminary work has also shown that KMT2B 
variants are associated with reduced transcript levels of both THAP1 and TOR1A in 
fibroblasts. It is proposed that variants in KMT2B affect the expression (including 
transcriptional stability and consistency) of a specific set of genes crucial to normal motor 
control.5 
 
 How to approach the investigation of a child with dystonia 
The discovery of KMT2B-related disease further highlights the clinical need for a systematic 
approach to the genetic investigation of early-onset dystonia. Dystonia may occur in isolation 
or associated with other neurological and systemic features. Careful clinical history and 
detailed examination can aid diagnosis and direct further diagnostic testing.  
 
Children with dystonia may often be labelled early in their disease course as having 
“dyskinetic” or “dystonic cerebral palsy”. However, a number of inherited conditions can 
mimic cerebral palsy and should be suspected, especially in the presence of “clinical red 
flags” which are rarely seen in acquired forms of cerebral palsy. Indeed, absence of a 
perinatal hypoxic ischemic insult, similarly affected family members, normal MRI brain (or 
neuroimaging features atypical for acquired cerebral palsy) and a progressive disease course 
would all increase clinical suspicion of an underlying genetic or neurometabolic condition 
(Yellow box, Figure 2). If neuroimaging and first-line neurometabolic investigations are 
negative, then genetic testing is the next step in the diagnostic algorithm (Figure 2).  
 
Chromosomal microarray should be considered as a first-line genetic evaluation in children 
and adults presenting with dystonia, especially in the presence of additional features such as 
dysmorphism or ID. In a single centre review of children and adults with movement 
disorders, 28% had a significant copy number variant (CNV) detected on routine diagnostic 
microarray.11 Pathogenic microdeletions encompassing causative genes have been described 
in individuals with dystonia (KMT2B), myoclonus-dystonia (SGCE) and benign hereditary 
chorea (TITF1).5,6,14,15 CNVs and are not usually detected on gene-panels or whole exome 
sequencing (WES), and pathogenic deletions and duplications could be potentially missed. 
However, over time, the increased availability of whole genome sequencing (WGS) will 
facilitate future CNV analysis.16 Chromosomal microarray should therefore be performed in 
all individuals presenting with dystonia associated with additional features. CNVs should also 
be excluded in those with a very distinct phenotype (e.g. myoclonus-dystonia) when direct 
Sanger sequencing is negative, either via microarray or targeted gene multiplex ligation-
dependent probe amplification (MLPA). 
 
In recent years, single gene testing has been generally surpassed by gene panels, a cost-
effective route by which to analyse multiple genes associated with a specific disorder.   
However, single gene testing may still have some clinical utility for distinct phenotypes (e.g.  
movement disorder with a low CSF:plasma glucose ratio – SLC2A1).17 A number of 
diagnostic targeted next-generation gene panels are now available, which sequence genes 
associated with movement disorders. Genes included in a gene panel will vary depending on 
the laboratory, and may not include newly identified dystonia genes. A retrospective review 
in a single tertiary centre estimated the diagnostic yield of a panel at 14.8% compared to 7.4% 
if the traditional route of consecutive single gene testing was undertaken.18 Some diagnostic 
gene panels will also offer MLPA to identify CNVs.  
 
At present, WES is becoming increasingly available in a clinical setting with a number of 
diagnostic laboratories undertaking clinical exomes for targeted gene analysis. The ability to 
interrogate WES data for recently identified genes is an added advantage, many of which are 
not always available immediately on established gene panels. However differential coverage 
of individual genes can be an issue.19 Research WES and WGS has certainly aided the 
identification of new disease-causing dystonia genes, as well as expanding the genotype and 
phenotype of known dystonia genes.2,4,9 Next generation sequencing should, therefore, be 
considered in patients with negative first tier investigations or atypical phenotypes. The 
diagnostic rate of WES in a single publication was 37.5%, with the yield likely to be higher in 
early onset generalised dystonia cohorts, where genetic dystonia is highly suspected.20  
 
Conclusion 
In conclusion, microdeletions and intragenic variants of KMT2B are an important cause of 
childhood-onset progressive dystonia.   Clues to diagnosis include early onset dystonia 
(usually of the lower limbs) with generalisation, and predominant cervical, oromandibular 
and laryngeal involvement.  Additional clinical features include neurological, dermatological, 
psychiatric and systemic features.   The identification of KMT2B should prompt early referral 
for GPI-DBS. For childhood dystonia suspected to be genetic in origin, microarray should be 
considered as a first-tier genetic investigation before performing gene panels and 
diagnostic/research WES and WGS. 
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Table 1: Summary of microdeletions and pathogenic variants reported to date 
Pat 
+ 
 
KMT2B variant 
Inheritance 
Age 
(y) 
Sex 
Presenting 
dystonia and 
other features 
Age (y) 
Current pattern of 
dystonia 
ID Dysmorphic 
features 
Other features Treatment-
Benefit 
DBS 
(age)- 
response 
MRI 
pattern 
* 
Age  
15 
(1) 
Deletion: 
chr.19:35,608,666 
-36,233,508 
De novo 
 
14 
M 
 
RLL 
R foot posturing 
Gait disturbance 
4 
BiLL, BiUL 
Oromandibular 
(dysarthria, swallowing 
difficulties) 
Laryngeal (dysphonia) 
Mild Elongated face NR L-dopa trial -  
no benefit 
No Yes 
9y5m 
25 
(2) 
Deletion: 
chr.19:35,197,252 
–38,140,100 
De novo 
14 
F 
BiLL 
Limping  
Gait disturbance 
7 
BiLL, BiUL 
Oromandibular 
(dysarthria, drooling) 
Laryngeal (dysphonia) 
No Elongated face 
Bulbous nasal tip 
NR L-dopa trial - no 
benefit 
BLF –  
no benefit 
No Yes 
13y1m 
35 
(3) 
Deletion: 
chr.19:34,697,740 
–37,084,510 
De novo 
9 
M 
RLL 
R foot posturing 
Gait disturbance 
2.5 
BiLL, BiUL 
Oromandibular 
(dysarthria, drooling, 
swallowing difficulties) 
Laryngeal (dysphonia) 
Mod Elongated face Dermatological 
(cutis aplasia) 
Systemic (retinal 
dystrophy)  
Mild global DD 
GBP - 
improvement in 
tone 
No Yes 
10y 
45 
(4) 
Deletion:  
chr.19:36,191,100 
–36,376,860 
De novo 
11 
F 
LLL 
L toe walking  
Gait disturbance 
4 
BiLL, BiUL 
Oromandibular 
(dysarthria, drooling, 
swallowing difficulties) 
Laryngeal (dysphonia) 
Very 
mild 
Elongated face 
Bulbous nasal tip 
Broad nasal bridge 
Psychiatric 
(prone to 
anxiety) 
L-dopa trial - 
minimal benefit 
THP –  
minimal benefit 
No Yes 
10y9m 
55 
(5) 
Deletion: 
chr.19:31,725,360 
–36,229,548 
De novo 
20 
M 
DD  
Gait disturbance 
Childhood-onset 
BiLL, BiUL 
Oromandibular (nasal 
voice) 
Mod Sparse hair 
Blepharophimosis 
Absent eye lashes 
of lower eyelids 
Low-set rotated ear 
Epicanthic folds 
Large bifid tongue 
Micrognathia 
Teeth overcrowding 
Finger contractures 
5th finger 
clinodactlyly 
Dermatological 
(cutis aplasia) 
Neurological 
(microcephaly) 
Systemic (small 
echogenic 
kidneys, renal 
transplant at 17y) 
Global DD 
None No NR 
65 
(6) 
Deletion: 
chr.19:35,017,972 
–36,307,788 
De novo 
10 
F 
RLL  
R foot inversion 
2.5 
BiLL, BiUL  
Cervical (torticollis, 
retrocollis) 
Oromandibular 
(dysarthria, then 
anarthria, jaw-opening 
dystonia, swallowing 
difficulties requiring 
PEG) 
No NR Neurological 
(microcephaly) 
L-dopa trial – 
no benefit 
THP- 
no benefit 
Yes (7y)-
clinical 
response 
Yes 
6y10m 
75 
(7) 
Deletion: 
chr.19:35,414,997 
–37,579,142 
De novo 
21 
M 
RLL 
R foot dragging 
Gait disturbance 
7 
BiLL, BiUL 
Oromandibular 
(dysarthria, swallowing 
difficulties) 
Laryngeal (dysphonia) 
Mild Elongated face Neurological 
(absence seizure) 
Systemic (absent 
R testis) 
Mild global DD 
L-dopa trial – 
no benefit 
BLF- 
no benefit 
No Yes 
13y3m 
85 
(8) 
Deletion: 
chr.19:35,414,997 –
37,579,142 
De novo 
17 
F 
RLL 
R foot posturing 
4 
BiLL, BiUL 
Cervical (torticollis) 
Oromandibular 
(drooling, dysarthria) 
Laryngeal (dysphonia) 
Mild Fifth finger 
clinodactlyly 
Dermatological 
(ectodermal 
dysplasia) 
L-dopa trial -no 
benefit 
Yes (6y)- 
clinical 
response 
Yes 
10y7m 
Yes 
12y 
95 
(9) 
Deletion: 
chr.19:35,967,904 –
37,928,373 
De novo 
14 
M 
BiLL 
Gait disturbance 
4 
BiLL, BiUL 
Oromandibular 
(dysarthria) 
Laryngeal (dysphonia) 
 
 
Mild Elongated face Neurological 
(strabismus) 
Systemic (cleft 
palate) 
Mild global DD 
L-dopa trial-
initial benefit, 
not sustained 
Yes (14y)-
clinical 
response 
Yes 
15y1m 
Pat 
+ 
 
KMT2B variant 
Inheritance 
Age 
(y) 
Sex 
Presenting 
dystonia and 
other features 
Age (y) 
Current pattern of 
dystonia 
ID Dysmorphic 
features 
Other features Treatment-
Benefit 
DBS 
(age)- 
response 
MRI 
pattern 
* 
Age 
105 
(10) 
Deletion: 
chr.19:35,794,775 –
38,765,822 
De novo 
7 
F 
BiLL 
Intermittent toe 
walking 
Gait disturbance 
4 
BiLL Mod NR Neurological 
(strabismus) 
Systemic  
(short stature, 
bronchiectasis) 
Mild global DD 
No No NR 
116,10 
 
Deletion: 
chr.19:33,203,635 -
38,108,990 
De novo 
23 
F 
NR 
NR 
Not specified Yes 
 
Long face  
High forehead  
Sparse eye lashes 
and eye brows 
Retrognathia,  
thin lips  
Clinodactlyly, long 
fingers, dysplastic 
nails 
Overlapping toes 
Neurological 
(microcephaly) 
Dermatological 
(cutis aplasia) 
Systemic 
(IUGR, CHD, 
short stature) 
DD 
NR NR NR 
126,11 
 
Deletion: 
chr.19:40,300,506 
– 40,925,348 
De novo 
NR 
NR 
NR 
4 
Progressive dystonia 
Gait disturbance 
 
Mild NR NR NR NR No^ 
136,12 
 
Deletion: 
chr.19:34,916,872 
- 36,661,836 
De novo 
14 
M 
BILL 
4 
Generalised  
Oromandibular  
Laryngeal (spasmodic 
dystonia with life 
threatening breathing 
episodes) 
Tremor 
Myoclonus 
Sev Narrow face  
Thick medially 
sparse eyebrows  
Hypertelorism  
Retrognathia. thin 
lips 
Low set ears with 
large lobules  
Clinodactyly of 5th 
fingers  
2nd and 3rd finger 
syndactyly R hand  
Bi-syndactyly of 
toes 
Neurological 
(microcephaly) 
Systemic (short 
stature, partial 
GH deficiency, 
low weight) 
DD 
Intrathecal BLF-  
some response 
Botox–  
some response 
Pimozide-  
some response 
NR No^ 
146 Deletion: chr. 
19:35,414,997 
- 37,579,142 
De novo 
NR 
F 
NR 
NR 
NR NR NR Dermatological 
(fine hair) 
NR NR NR 
155 
(11) 
c.402dup 
p.Ser135Glnfs*23 
De novo 
25 
F 
RUL  
R hand cramps 
and posturing 
6 
BiLL, BiUL  
Oromandibular (tongue 
thrusting, anarthria, 
swallowing difficulties 
needing PEG)  
Laryngeal 
No Bulbous nasal tip NR L-dopa trial- 
no benefit 
No Yes 
21y 
165 
(12) 
c.1690C>T 
p.Arg564* 
De novo 
6 
F 
BiLL  
Toe walking 
4 
BiLL, BiUL  
Oromandibular 
(dysarthria, swallowing 
difficulties) 
Mod Elongated face 
Bulbous nasal tip 
Short nasal root 
Hypertelorism 
Large mouth,  
full lower lip 
Neurological 
(epilepsy) 
Speech delay 
L-dopa trial- 
no benefit 
No NA 
3y3m 
175 
(13) 
c.3023_3027del 
p.Glu1009Glyfs*9 
De novo 
11 
M 
BiUL  
Tremor  
Difficulty with 
hand-writing 
8 
 
 
BiLL, BiUL  
Oromandibular 
(dysarthria)  
Laryngeal (dysphonia) 
Mild 
difficu
lties 
with 
attenti
on 
 
 
Elongated face Fine motor delay L-dopa trial- 
no benefit 
No Yes 
11y3m 
Pat 
+ 
 
KMT2B variant 
Inheritance 
Age 
(y) 
Sex 
Presenting 
dystonia and 
other features 
Age (y) 
Current pattern of 
dystonia 
ID Dysmorphic 
features 
Other features Treatment-
Benefit 
DBS 
(age)- 
response 
MRI 
pattern 
* 
Age 
185 
(14) 
c.3143_3149del 
p.Gly1048Glufs*132 
De novo 
18 
M 
BiUL  
Posturing of 
hands 
Myoclonic jerks 
8 
BILL, BiUL 
Oromandibular 
(dysarthria, swallowing 
difficulties requiring)  
Laryngeal (dysphonia) 
No Elongated face 
Bulbous nasal tip 
NR L-dopa trial- 
no benefit 
No Yes 
10y7m 
195 
(15) 
c.4545C>A  
p.Tyr1515* 
De novo 
20 
F 
BiLL  
Toe walking 
Clumsy 
2 
BILL, BiUL 
Oromandibular 
(dystonia, dysarthria, 
swallowing difficulties 
requiring PEG)  
Laryngeal (dysphonia) 
No Elongated face 
Bulbous nasal tip 
NR L-dopa, THP, 
CLZ, BLF- 
moderate 
response 
No Yes 
18y 
205 
(16) 
c.4688del 
p.Ala1563Aspfs*83 
De novo 
6 
F 
BiLL 
Gait disturbance  
Increase falls 
3 
BiLL, BiUL 
Oromandibular 
(dysarthria) 
Laryngeal (dysphonia) 
No Elongated face NR L-dopa trial- 
no benefit 
THP- 
initial benefit, 
not sustained 
No Yes 
4y9m 
Yes 
5y9m 
215 
(17) 
c.6515_6518delinCCC
AA 
p.Val2172Alafs*11 
De novo 
17 
M 
BiLL  
Toe walking  
Gait disturbance 
1 
BiLL, BiUL 
Oromandibular 
(dysarthria, swallowing 
difficulties) 
Laryngeal (dysphonia) 
No Elongated face Dermatological 
(phimosis) 
L-dopa trial- 
no benefit 
TBZ- 
no benefit 
BLF and THP-
minimal benefit 
Yes (16y) 
Clinical 
response, 
independent 
walking 
Yes 
14y8m 
225 
(18) 
c.8061del 
p.Tyr2688Thrfs*50 
De novo 
20 
F 
Clumsy 
movements 
Difficulties with 
speech 
articulation 
1 
Oromandibular 
(swallowing difficulties, 
dysarthria) 
Laryngeal (dysphonia) 
Mild Micrognathia 
Atrophic tongue 
Bulbous nasal tip 
5th-finger 
clinodactyly 
Delayed speech None No No 
20y 
235 
(19) 
c.8079del  
p.Ile2694Serfs*44 
De novo 
28 
M 
Bi LL 
Toe walking,  
Severe speech 
delay 
2 
BiLL, BiUL 
Cervical (torticollis, 
laterocollis) 
Oromandibular (jaw-
opening dystonia, tongue 
protrusion, anarthria, 
swallowing difficulties, 
PEG feeding) 
No No Neurological 
(delay in saccade 
initiation, 
hypometric 
vertical 
saccades) 
Systemic  
(short stature) 
Psychiatric 
(ADHD) 
L-dopa trial – 
no benefit 
TBZ and THP-
reduced tongue 
protrusion 
Yes (27y)-
Clinical 
response 
 
No 
23y 
248 c.4966_4968TCCdel 
p.Ser1656del 
De novo 
10 
F 
Microcephaly 
R hand dystonic 
tremor 
4 
BILL, BiUL, trunk 
Cervical 
Oromandibular 
(dysarthrophonia) 
Action induced 
myoclonus 
Mild No Neurological 
(microcephaly) 
Other (scoliosis) 
Anticholinergics- 
improved motor 
symptoms 
No No^ 
255 
(20) 
c.3528+2T>A 
Unknown 
40 
M 
L LL  
Dragging L foot  
Gait disturbance  
Clumsiness 
4 
BiLL, BiUL 
Cervical (torticollis) 
Oromandibular 
(dysarthria) 
Laryngeal (dysphonia) 
Mod NR NR L-dopa trial- 
no benefit 
TBZ, THP, SUL- 
no benefit 
 
Yes (32y)-
Clinical 
response 
No 
34y 
266 
(F1-II-
5) 
c.6406delC 
p.Leu2136Serfs*17 
De novo 
31 
F 
Inversion of L 
foot 
7 
BILL, BiUL 
Cervical 
Oromandibular (tongue) 
Laryngeal 
 
 
 
 
No NR NR L-dopa–  
no benefit 
Yes (23y)-
Clinical 
response 
No^ 
Pat 
+ 
 
KMT2B variant 
Inheritance 
Age 
(y) 
Sex 
Presenting 
dystonia and 
other features 
Age (y) 
Current pattern of 
dystonia 
ID Dysmorphic 
features 
Other features Treatment-
Benefit 
DBS 
(age)- 
response 
MRI 
pattern 
* 
Age 
276 
(F2-II-
1) 
c.1633C>T 
p.Arg545* 
De novo 
11 
F 
BiLL 
3 
BiLL, BiUL No NR Neurological 
(microcephaly 
and strabismus) 
Systemic (short 
stature, VUR) 
Moderate motor 
delay 
L-dopa- 
no benefit 
Anticholinergics 
–NR 
No No^ 
296 
(F4-III-
2) 
c.2482C>T 
p.Gln810* 
Paternal 
6 
F 
L foot 
4 
BiLL 
Cervical 
Mild NR Neurological 
(microcephaly, 
astigmatism) 
Systemic (short 
stature) 
Global DD 
L-dopa-  
NR 
No No^ 
306 
(F4-II-
4) 
c.2482C>T 
p.Gln810* 
Paternal 
36 
M 
Hand 
clumsiness 
9 
Hand- writer cramp 
Forearm 
Oromandibular 
(dysarthria) 
Mild NR Neurological 
(microcephaly, 
astigmatism) 
Systemic  
(short stature) 
Speech delay 
No No NR 
316 
(F4-I-
3) 
c.2482C>T 
p.Gln810* 
Unknown 
61 
M 
Hand 
clumsiness 
11 
Limb (writer-cramp) 
Forearm 
Oromandibular 
(dysarthria) 
R arm action induced 
tremor 
Mild NR Speech delay No No NR 
325 
(21) 
c.4955G>A 
p.Gly1652Asp 
De novo 
18 
M 
RLL  
R leg posturing 
6 
BiLL, BiUL 
Oromandibular 
(dysarthria, swallowing 
difficulties) 
Laryngeal (dysphonia) 
Mild Elongated face Systemic  
(short stature)  
Dermatological 
(hypertrichosis) 
L-dopa trial- 
no benefit  
THP- 
not tolerated 
Yes (15y)-
Clinical 
response 
 
NA 
10y5m 
15y3m 
335 
(22) 
c.4986C>A 
p.Phe1662Leu 
Maternal 
20 
F 
RLL  
R foot posturing  
Abnormal gait 
5 
BiLL, BiUL 
Cervical (torticollis)  
Oromandibular 
(dysarthria, swallowing 
difficulties)  
Laryngeal (dysphonia) 
No Elongated face  
Bulbous nasal tip 
NR L-dopa trial- 
no benefit 
THP- 
mild benefit 
BTX neck- 
no functional 
benefit 
Yes (20y)-
Clinical 
response 
Independent 
walking 
Yes 
13y1m 
Yes 
15y3m 
345 
(23) 
c.5114G>A 
p.Arg1705Gln 
De novo 
8 
M 
BiLL 
Toe walking 
3 
BiLL, BiUL 
Cervical (torticollis) 
Oromandibular 
(dysarthria) 
Mild- 
mod 
Elongated face  
Bulbous nasal tip  
Broad philtrum  
Up-slanted eyes 
Low-set ears  
Periorbital fullness  
Gap between front 
teeth 
Neurological 
(BILL spasticity) 
Dermatological 
(ichthyoid lesion,  
Systemic 
(episodic 
vomiting) 
Global DD 
L-dopa trial- 
no benefit 
CLZ, THP, IT 
BLF- some 
benefit 
Yes (7y)- 
Clinical 
response 
Yes 
6y6m 
Yes 
6y7m 
355 
(24) 
c.5284C>T 
p.Arg1762Cys 
De novo 
27 
F 
LLL  
Tip-toe walking 
In-turning L toe 
6 
BiLL, BiUL 
Oromandibular 
(dysarthria, anarthria, 
reduced tongue 
movement) 
No No Neurological 
(oculomotor 
apraxia with 
difficulty 
initiating 
saccades) 
Systemic (short 
stature) 
 
 
 
 
 
L-dopa trial- 
no benefit 
THP- 
no benefit 
No No 
20y 
No 
27y 
Pat 
+ 
 
KMT2B variant 
Inheritance 
Age 
(y) 
Sex 
Presenting 
dystonia and 
other features 
Age (y) 
Current pattern of 
dystonia 
ID Dysmorphic 
features 
Other features Treatment-
Benefit 
DBS 
(age)- 
response 
MRI 
pattern 
* 
Age 
365 
(25) 
c.5342T>C 
p.Leu1781Pro 
De novo 
19 
F 
RLL 
R foot posturing 
Gait disturbance 
8 
BiLL, BiUL 
Cervical (torticollis) 
Oromandibular 
(dysarthria, swallowing 
difficulties 
Laryngeal (dysphonia) 
No Elongated face  
Bulbous nasal tip 
NR L-dopa trial – 
no benefit 
LVT –  
mild benefit 
Yes (19y) 
Clinical 
response 
Improved 
walking 
Yes 
16y 
375 
(26a) 
c.7549C>T 
p.Arg2517Trp 
Maternal 
8 
M 
Delayed motor 
and speech 
development 
8 
Cervical (severe 
paroxysmal retrocollis) 
Oromandibular (jaw 
dystonia) 
 
No Bulbous nasal tip Psychiatric 
(ADHD) 
NR No No 
15m 
No 
8y 
38
5 
(26b) 
c.7549C>T 
p.Arg2517Trp 
De novo 
 
46 
F 
BiUL 
UL posturing 
Torticollis 
Inability to walk 
long distances or 
run 
23 
BiLL, BiUL 
Cervical (torticollis) 
Laryngeal (dysphonia) 
 
No Bulbous nasal tip Neurological 
(Idiopathic 
intracranial 
hypertension) 
No No  
395 
(27) 
c.8021T>C 
p.Ile2674Thr 
Maternal 
19 
F 
RUL 
Posturing 
Tremor  
Poor handwriting 
Myoclonic jerks 
9 
BILL, BiUL 
Oromandibular 
Laryngeal (dysphonia) 
Mild Bulbous nasal tip Psychiatric 
(anxiety, self-
harm, OCD) 
L-dopa trial- 
no benefit 
THP-no benefit 
LVT-no benefit 
CBZ-initial 
benefit, not 
sustained 
CLZ- 
not tolerated 
No NA 
10y10 
407 
(2) 
c.3700G>A 
p.Glu1234Lys 
De novo 
21 
M 
L LL dystonia-
exercise induced 
17 
BiLL, BiUL 
Cervical  
Oromandibular 
(dysarthria) 
Laryngeal (spasmodic 
dysphonia) 
No NR No L-dopa trial –  
no benefit  
Anticholinergics-
partial benefit 
No No^ 
417 
(3) 
c.4622C>T 
p.Ala1541Val^ 
Unknown 
60 
M 
Generalised 
43 
BiUL 
Cervical 
Oromandibular 
(dysarthria) 
Laryngeal (dysphonia)  
Tremor 
No NR No L-dopa trial Yes (53y)-
clinical 
response 
No^ 
427 
(4) 
c.5336G>A 
p.Arg1779Gln^ 
Unknown 
52 
F 
LL posturing 
7 
BiLL, BiUL, trunk 
Cervical (retro-
torticollis)  
Oromandibular (lingual, 
dysarthria) 
No NR   L-dopa trial Yes (43y)-
clinical 
response 
No^ 
439 
(7) 
c.4847C>T 
p.Ala1616Val 
De novo 
13 
F 
Trunk 
6 
BiLL, BiUL, trunk 
Cervical 
Mod Bulbous nasal tip Neurological 
(strabismus) 
Other (SNHL) 
NR NR No^ 
^, Not analyzed by Meyer and Colleagues; +, number in brackets refers to patient number in original paper; *, typical pattern of bilateral subtle hypointensity of the 
globus pallidi (especially the lateral aspect of the globus pallidus externa) on T2, diffusion and susceptibility weighted MRI images; BiLL, Bilateral lower limbs; BiUL, 
Bilateral upper limbs; BLF, baclofen; BTX, botulinum toxin; CLZ, clonazepam; CHD, congenital heart disease; CLZ, clonazepam; DD, developmental delay; F, female; 
GD, generalised dystonia; GBP, gabapentin; IT, intrathecal; IUGR, intra-uterine growth retardation; L, left; LL, lower limb; LVT, levetiracetam; M, male; m, months; 
mod, moderate; NA, not analysed; NR, not recorded; Pat, Patient; PEG, percutaneous endoscopic gastrostomy; Sev, severe; SNHL, sensorineural hearing loss; SUL, 
sulpiride; R, right; TBZ, tetrabenazine; THP, trihexyphenidyl; UL, upper limbs; y, years 
 
 
 
 
 
 
 
  
Legend 
 
Figure 1: Radiological features of KMT2B variants.  
MR imaging (Patient1, age 9 years, 5 months) T2-weighted(A), echo-planar technique 
diffusion image with b value of zero(B) and susceptibility-weighted sequences(C). Abnormal 
findings are indicated by yellow arrows with evidence of bilateral subtle hypointensity of the 
globus pallidus with hypointense lateral streak of globus pallidus externa. 
Figure is modified with permission from Meyer et al., 2017.  Mutations in the histone 
methyltransferase gene KMT2B cause complex early-onset dystonia. Nat Genet 
2017;49(2):223–37. 
 
 
Figure 2 Diagnostic algorithm for the investigation of a child presenting with dystonia 
*Neurometabolic investigations of dystonia  
Blood: Amino acids, lactate, creatine kinase, biotinidase, renal and liver profile, glucose, 
copper, caeruloplasmin, urate, thyroid function tests, ammonia, acylcarnitine profile 
Urine: Organic acids, copper, guanidinoacetate  
CSF: Neurotransmitters, glucose and lactate (paired with serum samples) 
^Sheffield Dystonia and Parkinson Panel (28 genes) 
AFG3L2, ANO3, ATP1A3, ATP7B, CYP27A1, FA2H, FTL, GBA, GCH1, GNAL, LRRK2, 
MAPT, PANK2, PARK2, PARK7, PINK1, PNKD, PRKCG, PRRT2, SGCE, SLC16A2, 
SLC2A1, SNCA, SPG11, SPR, TH, THAP1, WDR45 
CNV, Copy number variants; EBV, Epstein Barr Virus; ID, Intellectual disability; MLPA, 
Multiplex ligation-dependent probe amplification; MRI, Magnetic resonance imaging; WES, 
Whole exome sequencing; WGS, Whole genome sequencing 
 
 
 
Table 1: Table of KMT2B variants, dystonia phenotype, response to treatment and additional 
clinical features 
^, Not analyzed by Meyer and Colleagues; +, number in brackets refers to number in original 
paper; *, typical pattern of bilateral subtle hypointensity of the globus pallidi (especially the 
lateral aspect of the globus pallidus externa) on T2, diffusion and susceptibility weighted MRI 
images; BiLL, bilateral lower limbs; BiUL, bilateral upper limbs; BLF, baclofen; BTX, 
botulinum toxin; CLZ, clonazepam; CHD, congenital heart disease; CLZ, clonazepam; F, 
female; GD, generalised dystonia; GBP, gabapentin; IT, intrathecal; IUGR, intra-uterine 
growth retardation; L, left; LL, lower limb; LVT, levetiracetam; M, male; m, months; mod; 
moderate, NA, not analysed; NR, not recorded; Pat, patient; PEG, percutaneous endoscopic 
gastrostomy; Sev, severe; SNHL, sensorineural hearing loss; SUL, sulpiride; R, right; TBZ, 
tetrabenazine; THP, trihexyphenidyl; UL, upper limbs; y, years 
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